The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss therapy Wegovy, allowing its use against metabolic dysfunction-associated steatohepatitis (MASH),

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the company a first-mover advantage over rival Eli Lilly & Co. in the US market. The drug is cleared for adults with metabolic-associated

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced return prospects. See more.

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or overweight patients without diabetes lose just over 12% of their body weight in a late-stage trial, behind analyst expectations of 15%, according to FactSet.

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's Mounjaro which launched in the country eight months ago.

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and pharmacy-based services by summer 2026.